Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
feMMe: Mirena ± Metformin ± Weight Loss for Early Endometrial Cancer
NCT01686126Phase 2Active, not recruiting
- Sponsor
- Queensland Centre for Gynaecological Cancer Research
- Start
- Dec 2012
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of avatrombopag in endometrial endometrioid adenocarcinoma (EEA), Endometrial Hyperplasia With Atypia (EHWA), sponsored by Queensland Centre for Gynaecological Cancer Research. Started Dec 2012; status: active, not recruiting.
02
Drugs
avatrombopag
03
Conditions
endometrial endometrioid adenocarcinoma (EEA)Endometrial Hyperplasia With Atypia (EHWA)
Beyond the preview
Go deeper on NCT01686126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01686126.